PRKDC and non-small cell lung carcinoma: Analysis of previous studies related to immunotherapy found that in melanoma, NSCLC, and kidney cancer, patients with Prkdc mutations had response rates to ICIs of 53.8%, 75%, and 50%, respectively131,132.